4DMT has entered into an exclusive partnership with Otsuka Pharmaceutical to develop and commercialize its therapy 4D-150 for retinal diseases in the Asia-Pacific region.

Target Information

4D Molecular Therapeutics (4DMT), a late-stage biotechnology firm focused on developing targeted therapeutic solutions, has announced a strategic partnership with Otsuka Pharmaceutical Co., Ltd. This partnership centers on the development and commercialization of 4D-150, a promising treatment for retinal vascular diseases, specifically wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). With a goal of improving patient outcomes, the collaboration emphasizes innovative therapy aimed at reducing the treatment burden and preventing vision loss.

4D-150 represents a potential backbone therapy leveraging an advanced AAV vector platform developed by 4DMT. This therapy is designed to deliver long-lasting effects with a single, safe intravitreal injection, thus offering a revolutionary approach to managing retinal diseases that significantly affect millions globally.

Industry Overview in Asia-Pacific

The Asia-Pacific (APAC) region is exhibiting a rapid increase in the incidence of retinal diseases such as wet AMD and DME, driven by an aging population and rising prevalence of diabe